Annual Reports

Additional Reports

Shareholder Derivative Settlement Documents

Additional Reports

Shareholder Derivative Settlement Documents

Additional Reports

Shareholder Derivative Settlement Documents

Additional Reports

Shareholder Derivative Settlement Documents

QUARTERLY EARNING REPORTS

Q1

Press Release

Financial Statements

Q2

Press Release

Financial Statements

Q3

Press Release

Financial Statements

Q4

Press Release

Financial Statements

Driving Sustainable Growth
and Innovation

Emcure is committed to creating long-term value through innovation, operational excellence, and a steadfast focus on delivering impactful healthcare solutions. Guided by a strong foundation of integrity and performance, we strive to achieve sustainable growth while addressing critical medical needs globally.

loading widget to trade EMCURE

Shareholder’s
Information

Explore

Shareholder’s Information

Explore

Disclosures under
Regulation 46

Explore

Disclosures under Regulation 46

Explore

Annual Reports of Subsidiary

Explore

Annual Reports of Subsidiary

Explore

Archives

Explore

Archives

Explore

Investor
Presentations

Explore

Investor Presentations

Explore

Committees
of the Board

Explore

Committees of the Board

Explore

FY 2024-25 (9M performance)

Compound annual total return to shareholders over the last 5 fiscal years
0 %
Total FY24 revenues, an increase of 2% in local currency
$ 0 B
FY24 adjusted EPS, a 2% increase over FY23 adjusted EPS; $11.44 FY24 GAAP EPS, a 6% increase.
$ 0
Compound annual total return to shareholders over the last 5 fiscal years
$ 0 B
FY24 cash returned to shareholders
$ 0 B
FY24 adjusted EPS, a 2% increase over FY23 adjusted EPS; $11.44 FY24 GAAP EPS, a 6% increase.
$ 0